See more : General Packer Co., Ltd. (6267.T) Income Statement Analysis – Financial Results
Complete financial analysis of Evolent Health, Inc. (EVH) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Evolent Health, Inc., a leading company in the Medical – Healthcare Information Services industry within the Healthcare sector.
- Daiwa Securities Living Investment Corporation (8986.T) Income Statement Analysis – Financial Results
- SinterCast AB (publ) (0HW9.L) Income Statement Analysis – Financial Results
- TaiwanJ Pharmaceuticals Co., Ltd. (6549.TWO) Income Statement Analysis – Financial Results
- Argos Resources Ltd (ARG.L) Income Statement Analysis – Financial Results
- Alok Industries Limited (ALOKTEXT.BO) Income Statement Analysis – Financial Results
Evolent Health, Inc. (EVH)
Industry: Medical - Healthcare Information Services
Sector: Healthcare
Website: https://www.evolenthealth.com
About Evolent Health, Inc.
Evolent Health, Inc., a healthcare company, through its subsidiary, Evolent Health LLC, provides clinical and administrative solutions to payers and providers in the United States. It operates in two segments, Evolent Health Services and Clinical Solutions. The Evolent Health Services segment provides an integrated administrative and clinical platform for health plan administration and population health management. It offers financial and administrative management services, such as health plan services, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients, population health performance that delivers patient-centric cost-effective care. The Clinical Solutions segment offers specialty care management services support a range of specialty care delivery stakeholders during their transition from fee-for-service to value-based care, independent of their stage of maturation and specific market dynamics in oncology and cardiology; and holistic total cost of care improvement. The company was founded in 2011 and is headquartered in Arlington, Virginia.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.96B | 1.35B | 907.96M | 1.02B | 846.38M | 627.06M | 434.95M | 254.19M | 96.88M | 0.00 | 25.67M | 8.35M |
| Cost of Revenue | 1.50B | 1.04B | 657.55M | 701.37M | 513.06M | 327.83M | 269.35M | 155.18M | 57.40M | 0.00 | 30.02M | 11.27M |
| Gross Profit | 460.47M | 316.58M | 250.41M | 321.06M | 333.32M | 299.24M | 165.60M | 99.01M | 39.48M | 0.00 | -4.35M | -2.93M |
| Gross Profit Ratio | 23.45% | 23.42% | 27.58% | 31.40% | 39.38% | 47.72% | 38.07% | 38.95% | 40.75% | 0.00% | -16.93% | -35.08% |
| Research & Development | 0.00 | 27.00M | 15.50M | 15.10M | 19.80M | 18.20M | 17.20M | 11.10M | 5.80M | 0.00 | 2.00M | 0.00 |
| General & Administrative | 0.00 | 0.00 | 219.50M | 310.55M | 392.82M | 306.31M | 205.67M | 160.69M | 75.29M | 0.00 | 15.60M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 358.11M | 269.27M | 219.50M | 310.55M | 392.82M | 306.31M | 205.67M | 160.69M | 75.29M | 0.00 | 15.60M | 15.98M |
| Other Expenses | 173.57M | 67.20M | 60.04M | 61.48M | 60.91M | 109.00K | 171.00K | 4.00K | 7.17M | -25.25M | 1.00K | 0.00 |
| Operating Expenses | 531.68M | 336.46M | 279.54M | 372.03M | 453.73M | 350.82M | 238.04M | 177.92M | 82.45M | -25.25M | 16.81M | 16.69M |
| Cost & Expenses | 2.04B | 1.37B | 937.09M | 1.07B | 966.79M | 678.65M | 507.39M | 333.09M | 139.85M | -25.25M | 46.83M | 27.96M |
| Interest Income | 5.26M | 1.37M | 407.00K | 3.16M | 3.99M | 3.44M | 1.66M | 0.00 | 0.00 | 0.00 | 0.00 | 18.00K |
| Interest Expense | 54.21M | 15.57M | 25.43M | 28.34M | 14.53M | 5.48M | 3.64M | 723.00K | 293.00K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 123.42M | 90.25M | 60.04M | 60.84M | 66.64M | 44.52M | 32.37M | 17.22M | 7.17M | 0.00 | 1.21M | 114.00K |
| EBITDA | -24.79M | 43.75M | 55.66M | -241.38M | -245.95M | -4.15M | -40.40M | -220.31M | -31.51M | -25.25M | -20.35M | -19.51M |
| EBITDA Ratio | -1.26% | 0.54% | 9.94% | 2.31% | -7.73% | -1.32% | -9.20% | 38.10% | -464.44% | 0.00% | -257.85% | -233.70% |
| Operating Income | -71.21M | -59.84M | 30.25M | -37.88M | -120.41M | -47.48M | -72.84M | -237.42M | -42.97M | -25.25M | -21.16M | -19.62M |
| Operating Income Ratio | -3.63% | -4.43% | 3.33% | -3.71% | -14.23% | -7.57% | -16.75% | -93.40% | -44.36% | 0.00% | -82.41% | -235.07% |
| Total Other Income/Expenses | -131.19M | -65.72M | 12.61M | -67.69M | -18.23M | -6.67M | -3.56M | -114.00K | 386.26M | -25.25M | 41.19M | 19.00K |
| Income Before Tax | -202.41M | -62.08M | -29.80M | -337.80M | -327.12M | -54.15M | -76.40M | -237.53M | 343.29M | -25.25M | 20.03M | -19.60M |
| Income Before Tax Ratio | -10.31% | -4.59% | -3.28% | -33.04% | -38.65% | -8.64% | -17.57% | -93.45% | 354.35% | 0.00% | 78.03% | -234.84% |
| Income Tax Expense | -89.37M | -43.38M | 483.00K | -3.55M | -21.54M | 40.00K | -6.64M | -10.76M | 23.48M | 0.00 | 8.00K | 337.00K |
| Net Income | -113.04M | -18.70M | -30.28M | -334.25M | -305.58M | -52.66M | -60.67M | -159.74M | 332.49M | -25.25M | 20.02M | -19.26M |
| Net Income Ratio | -5.76% | -1.38% | -3.34% | -32.69% | -36.10% | -8.40% | -13.95% | -62.84% | 343.21% | 0.00% | 78.00% | -230.81% |
| EPS | -1.28 | -0.20 | -0.35 | -3.94 | -3.71 | -0.68 | -0.94 | -3.55 | 13.14 | -0.66 | 0.06 | -1.13K |
| EPS Diluted | -1.28 | -0.20 | -0.35 | -3.94 | -3.71 | -0.68 | -0.94 | -3.55 | 6.93 | -0.66 | 0.06 | -1.13K |
| Weighted Avg Shares Out | 111.25M | 93.70M | 86.07M | 84.93M | 82.36M | 77.34M | 64.35M | 45.00M | 25.13M | 38.23M | 38.23M | 17.00K |
| Weighted Avg Shares Out (Dil) | 111.25M | 93.70M | 86.07M | 84.93M | 82.36M | 77.34M | 64.35M | 45.03M | 46.14M | 38.23M | 38.23M | 17.00K |
Evolent Announces Second Quarter 2023 Results
Evolent welcomes Toyin Ajayi to its Board of Directors
Evolent Health: Business Economics Still Appealing, Reiterate Buy
Evolent to Release Second Quarter Financial Results on Wednesday, August 2, 2023
Evolent Health announces focus on value-based specialty care with rebrand, unification of all solutions under "Evolent"
Evolent Health, Inc. (EVH) Q1 2023 Earnings Call Transcript
Evolent Health (EVH) Beats Q1 Earnings Estimates
Evolent Health Announces First Quarter 2023 Results
Evolent Health Names New Independent Nominee for Election to Board of Directors
Evolent Health and Centene Agree to Expanded Partnership for Oncology Specialty Care for Medicare Advantage Members
Source: https://incomestatements.info
Category: Stock Reports